跳至主要内容
临床试验/EUCTR2013-001682-16-AT
EUCTR2013-001682-16-AT进行中(未招募)1 期

A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis

AbbVie Deutschland GmbH & Co. KG0 个研究点目标入组 840 人开始时间: 2014年6月16日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
840

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1)Subject is between the ages of 18 to 75 years
  • 2) Diagnosis of UC for at least 90 days, confirmed by endoscopy (colonoscopy or flexible sigmoidoscopy) during the Screening Period
  • 3) Active ulcerative colitis with a Mayo Score of 6 – 12 points and endoscopy subscore of 2 – 3 despite concurrent treatment with oral corticosteroids or immunosuppressants or both
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 683
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 157

排除标准

  • 1. Subject with Crohn's disease (CD) or indeterminate colitis (IC).
  • 2. Current diagnosis of fulminant colitis and/or toxic megacolon.
  • 3. Subjects with disease limited to the rectum (ulcerative proctitis) during the screening endoscopy.
  • 4. Chronic recurring infections or active TB

研究者

相似试验

进行中(未招募)
1 期
A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
EUCTR2013-001682-16-ITAbbVie Deutschland GmbH & Co. KG952
进行中(未招募)
1 期
A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitislcerative colitisMedDRA version: 19.0Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856
EUCTR2013-001682-16-NLAbbVie Deutschland GmbH & Co. KG840
进行中(未招募)
1 期
A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative ColitisMedDRA version: 20.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 100000004856Ulcerative colitis
EUCTR2013-001682-16-DKAbbVie Deutschland GmbH & Co. KG840
进行中(未招募)
1 期
A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitislcerative colitisMedDRA version: 19.0Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856
EUCTR2013-001682-16-CZAbbVie Deutschland GmbH & Co. KG840
进行中(未招募)
1 期
A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitislcerative colitisMedDRA version: 16.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856
EUCTR2013-001682-16-HUAbbVie Deutschland GmbH & Co. KG952